.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Chinese Patent Office
Cerilliant
Queensland Health
Harvard Business School
Julphar
Fish and Richardson
Johnson and Johnson
Citi

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,911,461

« Back to Dashboard

Which drugs does patent 6,911,461 protect, and when does it expire?


Patent 6,911,461 protects BRIVIACT and is included in three NDAs.

This patent has one hundred and thirty-seven patent family members in forty-one countries.

Summary for Patent: 6,911,461

Title: 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
Abstract:The invention concerns 2-oxo-1-pyrrolidine derivatives of formula I, ##STR1## wherein the substituents are as defined in the specification, as well as their use as pharmaceuticals. The compounds of the invention are particularly suited for treating neurological disorders such as epilepsy.
Inventor(s): Differding; Edmond (Louvain-la Neuve, BE), Kenda; Benoit (Emines, BE), Lallemand; Benedicte (Waimes, BE), Matagne; Alain (Gerpinnes, BE), Michel; Philippe (Beersel, BE), Pasau; Patrick (Chastre, BE), Talaga; Patrice (Watermael-Boitsfort, BE)
Assignee: UCB, S.A. (Brussels, BE)
Application Number:10/693,917
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Ucb IncBRIVIACTbrivaracetamSOLUTION;INTRAVENOUS205837-001May 12, 2016RXYesYes► Subscribe► Subscribe► SubscribeYY
Ucb IncBRIVIACTbrivaracetamSOLUTION;INTRAVENOUS205837-001May 12, 2016RXYesYes► Subscribe► Subscribe► SubscribeYYTREATMENT OF PARTIAL-ONSET SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY
Ucb IncBRIVIACTbrivaracetamSOLUTION;ORAL205838-001May 12, 2016RXYesYes► Subscribe► Subscribe► SubscribeYYTREATMENT OF PARTIAL-ONSET SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY
Ucb IncBRIVIACTbrivaracetamSOLUTION;ORAL205838-001May 12, 2016RXYesYes► Subscribe► Subscribe► SubscribeYY
Ucb IncBRIVIACTbrivaracetamTABLET;ORAL205836-001May 12, 2016RXYesNo► Subscribe► Subscribe► SubscribeYYTREATMENT OF PARTIAL-ONSET SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY
Ucb IncBRIVIACTbrivaracetamTABLET;ORAL205836-001May 12, 2016RXYesNo► Subscribe► Subscribe► SubscribeYY
Ucb IncBRIVIACTbrivaracetamTABLET;ORAL205836-002May 12, 2016RXYesNo► Subscribe► Subscribe► SubscribeYYTREATMENT OF PARTIAL-ONSET SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY
Ucb IncBRIVIACTbrivaracetamTABLET;ORAL205836-002May 12, 2016RXYesNo► Subscribe► Subscribe► SubscribeYY
Ucb IncBRIVIACTbrivaracetamTABLET;ORAL205836-003May 12, 2016RXYesNo► Subscribe► Subscribe► SubscribeYY
Ucb IncBRIVIACTbrivaracetamTABLET;ORAL205836-003May 12, 2016RXYesNo► Subscribe► Subscribe► SubscribeYYTREATMENT OF PARTIAL-ONSET SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,911,461

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0004297Feb 23, 2000

Non-Orange Book Patents for Patent: 6,911,461

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,358,2762-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses► Subscribe
6,713,635 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses► Subscribe
7,692,0282-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses► Subscribe
8,034,9582-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses► Subscribe
7,217,8262-oxo-1-pyrrolidine derivatives, process for preparing them and their uses► Subscribe
6,858,740 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses► Subscribe
8,492,4162-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses► Subscribe
6,969,770 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses► Subscribe
6,806,287 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses► Subscribe
6,784,197 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,911,461

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan4769756► Subscribe
Iceland7923► Subscribe
Japan2003528828► Subscribe
Japan4081275► Subscribe
Japan2003523996► Subscribe
Japan4121744► Subscribe
Austria304999► Subscribe
Austria325093► Subscribe
Austria445597► Subscribe
Austria488500► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Dow
US Army
Johnson and Johnson
QuintilesIMS
Fuji
Medtronic
Argus Health
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot